# Saruparib in HRDsig+ Solid Tumors

Source: https://onco.cc/trials/nct07832630/  
OnCo record `nct07832630` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT07832630 as not yet recruiting, last updated 2026-09-22. Enrolment is 124 planned participants, an estimate. Interventions: Saruparib, FoundationOne®CDx. Primary measures include Best objective response as determined by RECIST v.1.1. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT07832630
- Phase: 2
- Setting: A Phase II Study of Saruparib in Patients With Platinum-Sensitive, HRDsig+ Solid Tumors
- Sponsor: Abramson Cancer Center at Penn Medicine

## Sources

- ClinicalTrials.gov NCT07832630: https://clinicaltrials.gov/study/NCT07832630

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct07832630.json